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Abstract
© 2017 Deneka et al. This is an open access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original author and source are credited. Non-small cell lung cancer
(NSCLC) is the leading cause of cancer death worldwide, with a 5-year survival of only 16%.
Potential strategies to address NSCLC mortality include improvements in early detection and
prevention, and development of new therapies suitable for use in patients with early and late
stage diagnoses. Controlling the growth of early stage tumors could yield significant clinical
benefits for patients with comorbidities that make them poor candidates for surgery: however,
many drugs that  limit  cancer  growth are not  useful  in  the setting of  long-term use or  in
comorbid patients, because of associated toxicities. In this study, we explored the use of a
recently described small molecule agent, STA-8666, as a potential agent for controlling early
stage tumor growth. STA-8666 uses a cleavable linker to merge a tumor-targeting moiety that
binds heat shock protein 90 (HSP90) with the cytotoxic chemical SN38, and has been shown to
have high efficacy and low toxicity, associated with efficient tumor targeting, in preclinical
studies using patient-derived and other xenograft models for pancreatic, bladder, and small cell
lung cancer. Using a genetically engineered model of NSCLC arising from induced mutation of
KRas and knockout of Trp53, we continuously dosed mice with STA-8666 from immediately after
tumor induction for 15 weeks. STA-8666 significantly slowed the rate of tumor growth, and was
well tolerated over this extended dosing period. STA-8666 induced DNA damage and apoptosis,
and reduced proliferation and phosphorylation of the proliferation-associated protein ERK1/2,
selectively in tumor tissue. In contrast, STA-8666 did not affect tumor features, such as degree
of vimentin staining, associated with epithelial-mesenchymal transition (EMT), or downregulate
tumor  expression  of  HSP90.  These  data  suggest  STA-8666  and  other  similar  targeted
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